Oxytocin: Molecular Structure

Molecular Structure Overview#

Oxytocin is a cyclic nonapeptide hormone with a molecular formula of C43H66N12O12S2 and a molecular weight of 1007.19 Daltons. The CAS number is 50-56-6. It was the first peptide hormone to be chemically synthesized, achieved by Vincent du Vigneaud in 1953, an accomplishment recognized with the Nobel Prize in Chemistry in 1955.

The structure of oxytocin consists of a 20-membered ring formed by an intramolecular disulfide bond between the two cysteine residues at positions 1 and 6, with a linear tripeptide tail (Pro-Leu-Gly-NH2) extending from Cys6. The C-terminal glycine is amidated, which is essential for biological activity.

Amino Acid Sequence#

The complete amino acid sequence of oxytocin is:

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2

In single-letter code: CYIQNCPLG-NH2 (with disulfide bond between C1 and C6)

Structural Features#

The oxytocin molecule has several critical structural elements:

• Disulfide bridge (Cys1-Cys6): Forms a 20-membered ring (tocin ring) that is essential for receptor binding and biological activity. Reduction of this disulfide bond completely abolishes activity
• C-terminal amide: The glycine at position 9 is converted to glycinamide (-CONH2). This modification is critical; the free carboxyl form has dramatically reduced activity
• Tocin ring: The six-residue ring (Cys-Tyr-Ile-Gln-Asn-Cys) adopts a beta-turn conformation that presents key pharmacophoric elements to the receptor
• Linear tail (Pro-Leu-Gly-NH2): The tripeptide tail contributes to receptor selectivity, distinguishing oxytocin binding from vasopressin receptor binding

Comparison with Vasopressin#

Oxytocin and arginine vasopressin (AVP) are evolutionarily related nonapeptides that differ at only two positions:

The differences at positions 3 (Ile vs Phe) and 8 (Leu vs Arg) are responsible for the distinct receptor selectivity profiles. Despite the structural similarity, these two substitutions produce dramatically different biological activities: oxytocin primarily mediates uterine contraction and social behavior, while vasopressin primarily mediates water retention and vasoconstriction.

Three-Dimensional Structure#

Crystal and Solution Structure#

The three-dimensional structure of oxytocin has been determined by X-ray crystallography and NMR spectroscopy. The PDB entry 1XY2 provides coordinates for oxytocin. In solution, the tocin ring adopts a type II beta-turn conformation involving residues 3-6 (Ile-Gln-Asn-Cys), which is stabilized by intramolecular hydrogen bonds.

The ring structure is relatively rigid due to the disulfide constraint, while the tripeptide tail is more flexible. The overall molecular shape can be described as a compact ring with a short flexible extension. This combination of rigidity and flexibility is important for receptor engagement.

Receptor Interaction#

Oxytocin binds to the oxytocin receptor (OXTR), a class A (rhodopsin-like) G protein-coupled receptor (GPCR). The receptor has seven transmembrane helices with an extracellular N-terminus and intracellular C-terminus. Key aspects of the oxytocin-OXTR interaction include:

• The tocin ring inserts into the binding pocket formed by transmembrane helices
• Tyr2 makes critical contacts with the receptor through aromatic interactions
• The disulfide ring provides the structural scaffold for proper pharmacophore presentation
• The C-terminal amide participates in hydrogen bonding with the receptor
• Ile3 and Leu8 contribute to receptor selectivity over vasopressin receptors

Cross-Reactivity#

Due to the high structural similarity between oxytocin and vasopressin, there is some cross-reactivity with vasopressin receptors (V1a, V1b, V2). Oxytocin has weak agonist activity at V1a and V2 receptors, which can manifest as vasopressor effects and antidiuretic effects at high doses. This cross-reactivity is clinically relevant because it underlies the risk of water intoxication and hyponatremia with prolonged high-dose oxytocin infusion.

Pharmacokinetic Properties#

Intravenous Administration#

Following intravenous injection, oxytocin has a very short plasma half-life of approximately 3-5 minutes. It is rapidly cleared from the circulation by the liver and kidneys. The enzyme oxytocinase (cystine aminopeptidase, also called leucyl/cystinyl aminopeptidase) is the primary enzyme responsible for oxytocin degradation, cleaving the Cys1-Tyr2 bond. During pregnancy, oxytocinase levels increase dramatically (up to 10-fold), which helps regulate circulating oxytocin levels.

The volume of distribution is relatively small due to oxytocin's hydrophilic nature. Uterine response to IV oxytocin begins within minutes, with steady-state contractions achieved after 20-40 minutes of continuous infusion.

Intranasal Administration#

Intranasal oxytocin delivery has been extensively used in behavioral and psychiatric research. Following intranasal administration at typical research doses (20-40 IU), oxytocin reaches the CNS through several proposed routes:

1. Direct nose-to-brain transport: Via olfactory and trigeminal nerve pathways
2. Systemic absorption and BBB penetration: Limited due to large molecular size and BBB impermeability
3. Circumventricular organs: Brain regions lacking a blood-brain barrier

The extent to which intranasal oxytocin achieves pharmacologically relevant concentrations in deep brain structures (amygdala, hypothalamus) remains debated. CSF concentrations of oxytocin rise after intranasal administration, but the magnitude and regional distribution within the brain are not fully characterized.

Metabolism and Elimination#

Oxytocin is metabolized primarily by oxytocinase (in plasma) and by non-specific peptidases in the liver and kidneys. Metabolites are excreted renally. The rapid metabolism is a significant pharmaceutical challenge, necessitating continuous IV infusion for obstetric applications and repeated intranasal dosing for research applications.

Physical and Chemical Properties#

Analytical Methods#

Oxytocin is quantified using validated immunoassays (radioimmunoassay, ELISA) and LC-MS/MS methods. Immunoassays remain widely used but suffer from cross-reactivity with vasopressin and oxytocin metabolites. LC-MS/MS provides greater specificity and is the preferred method for accurate plasma oxytocin measurement. Sample handling is critical, as oxytocin degrades rapidly in whole blood and plasma if not properly preserved with protease inhibitors and rapid freezing.

Related Reading#

• Oxytocin overview and research guide
• Peptides similar to Oxytocin
• Oxytocin research evidence